Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones

168Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Dibenz[b,f][1,4]oxazepin-11(10H)-ones (III), pyrido[2,3-b] [1,4]benzoxazepin-6(5fl)-ones (IV), and pyrido[2,3-b]-[1,5]benzoxazepin-5(6H)-ones (V) were found to inhibit human immunodeficiency virus type 1 reverse transcriptase with IC50 values as low as 19 nM. A-ring substitution has a profound effect on activity, with appropriate substituents at the positions ortho and para to the lactam nitrogen providing dramatically enhanced potency. Substitution in the C-ring is generally neutral or detrimental to activity. Although a C-ring amino substituent at the position meta to the lactam carbonyl is generally beneficial to activity, it has essentially no effect when the A-ring is optimally substituted. Like the dipyridodiazepinone nevirapine, compounds III-V are specific for HIV-1 RT, exhibiting no inhibitory activity against HIV-2 RT or other virial reverse transcriptase enzymes. © 1992, American Chemical Society. All rights reserved.

Cite

CITATION STYLE

APA

Klunder, J. M., Hargrave, K. D., West, M. A., Cullen, E. E., Pal, K. E., Behnke, M. L., … Adams, J. (1992). Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones. Journal of Medicinal Chemistry, 35(10), 1887–1897. https://doi.org/10.1021/jm00088a027

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free